XML 17 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Operating expenses:        
Research and development $ 5,704 $ 1,930 $ 15,455 $ 4,644
Research and development, related party 285 17 988 286
General and administrative 3,394 312 8,526 888
Total operating expenses 9,383 2,259 24,969 5,818
Loss from operations (9,383) (2,259) (24,969) (5,818)
Other income (expense):        
Change in fair value of redeemable convertible preferred stock tranche liability 0 0 (11,718) 0
Foreign currency gain (loss) (252) 1 (268) 13
Other income, net 20 0 20 0
Total other income (expense) (232) 1 (11,966) 13
Net loss (9,615) (2,258) (36,935) (5,805)
Accretion of redeemable convertible preferred stock to redemption value and cumulative preferred stock dividends (1,322) (461) (4,548) (1,352)
Net loss attributable to common stockholders $ (10,937) $ (2,719) $ (41,483) $ (7,157)
Net loss per share attributable to common stockholders, basic and diluted $ (0.70) $ (1.46) $ (5.49) $ (3.85)
Weighted Average Number of Shares Outstanding, Basic and Diluted 15,585,611 1,863,860 7,554,300 1,859,713
Comprehensive loss:        
Net loss $ (9,615) $ (2,258) $ (36,935) $ (5,805)
Other comprehensive loss        
Unrealized Gain (Loss) on Investments (18) 0 (18) 0
Comprehensive loss $ (9,633) $ (2,258) $ (36,953) $ (5,805)